Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

  • Contact us:

    Campus Charité MitteCharitéplatz 1 (Geländeadresse: Virchowweg 20)
    10117 Berlin

  • Accessibility:
    Contrast Settings Change contrast
    Font size
    Font size bigger: STRG+ Font size smaller: STRG-

    You can enlarge or reduce the browser window. Please use CTRL and + to zoom in or CTRL and - to zoom out. Press CTRL and 0 to reset your browser window to normal size.

Open Menu
Eine Nahaufname mit Tiefenunschärfe von mehreren, übereinander gelegten Tageszeitungen.

Press release

23.01.2023

Inborn immunodeficiency discovered – and explained

Back to Overview

You are here:

Analysis of IRF4 (colored brown) in a form of lymphoma. © Institute of Pathology at the University Hospital of Würzburg | Prof. I. Anagnostopoulos

Joint press release by Charité and the Max Delbrück Center

A group of international researchers has found that changing a single segment of the genome causes a previously unknown immunodeficiency in humans. Amongst others, the study was led by scientists from the Experimental and Clinical Research Center, a joint institution of Charité – Universitätsmedizin Berlin and the Max Delbrück Center. The paper, which is published in Science Immunology*, reports the discovery of a specific mutation in the gene regulator IRF4.

In a study of seven children with profound immunodeficiency, an international consortium of researchers has discovered a T95R mutation in the gene for interferon regulatory factor 4. IRF4 is a transcription factor that controls proteins, which means it regulates how much messenger RNA a cell produces. But it also plays a key role in the development and activation of immune cells. The seven patients came from six unrelated families living on four different continents. The research team, which includes the group led by Prof. Dr. Stephan Mathas and PD Dr. Martin Janz at the ECRC, were also able to identify how the mutation affects the immune system. A previously undescribed mechanism causes an inborn combined immunodeficiency.

Inborn immunodeficiencies are rare and often vary in severity. “Immunodeficient children frequently contract infections of the upper airways,” says Prof. Mathas. The illnesses are often caused by Epstein-Barr virus, cytomegalovirus, or Pneumocystis jirovecii, a pathogen that causes pneumonia. These are all infections that physicians regularly see in other patients with immunodeficiencies.

The seven patients in this study also suffer from these infections. When the researchers delved deeper, they found that the children’s immune systems shared some similarities: “All the children have too few antibodies in their blood and very few B cells, which normally produce the antibodies. They also have fewer T cells than healthy individuals, and the T cells they do have function less well,” says Prof. Mathas. Alongside B cells and antibodies, T cells are an important pillar of the immune system.

In many children who are born with an immunodeficiency, the cause of the condition is unknown. Today, though, genome sequencing can help shed light on it. This was how the study’s authors discovered the T95R mutation in IRF4. By collaborating closely in international networks, the researchers traced the genetic cause of the disease in these children from unrelated families to the same point mutation. This makes them the index patients – the first described cases – for this deficiency. The consortium was also able to produce the same syndrome in mice by specifically mutating IRF4. This allowed the researchers to gain a more detailed understanding of the errors of immunity caused by IRF4.

The T95R mutation is only ever found on one of the two copies of the genome. And although the patients also always produce healthy IRF4, they all develop the immunodeficiency. “The biology of the mutation effectively beats the biology of the healthy form,” says Prof. Mathas. Genome analysis of the families revealed that the index patients didn’t inherit the mutation from their parents. Rather, it occurred spontaneously in the germline or during early embryonic development.

The mutation in the gene regulator IRF4 occurs at the precise location where it binds to DNA. “In conjunction with other factors, the mutation changes IRF4’s affinity for DNA,” says Prof. Mathas. This means that, as well as binding to known DNA binding sites with varying degrees of strength depending on the context, the mutated IRF4 protein also binds to parts of the genome that it shouldn’t be involved in at all – sites that the normal variant of the protein would never bind to. Bioinformatics analyses allowed the researchers to identify these new binding sites. They describe the mutation in their paper as “multimorphic” because as well as blocking certain genes, it also activates others – and even new ones.

Depending on the type and severity of an inborn immunodeficiency, patients might undergo stem cell transplants or receive regular antibody injections throughout their lives. “Now our study suggests that it would be possible to change a mutated transcription factor’s binding sites without affecting the healthy variant,” says Prof. Mathas.

The T95R mutation in IRF4 will now be added to the catalogue of genes used to diagnose inborn immunodeficiency. Interestingly, IRF4 also plays an important role in the development of certain types of blood cancer, which Prof. Mathas and his team are also investigating.

*Fornes O et al. A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency. Sci Immunol 2023 Jan 20. doi: 10.1126/sciimmunol.ade7953

About the study
In addition to the two German research groups – from Charité/Max Delbrück Center and the University of Ulm – the consortium includes researchers from children’s hospitals and universities in Canberra (Australia), Shanghai (China), Vancouver (Canada), Paris (France) and Nashville (USA), as well as from the National Institutes of Health in Bethesda (USA).

Links

Original article
Janz/Mathas lab at the ECRC

Contact

Prof. Dr. Stephan Mathas
Experimental and Clinical Research Center (ECRC)
Charité – Universitätsmedizin Berlin und Max Delbrück Center
t: +49 30 450 553 112



Back to Overview